Key result
Pregnant women with preeclampsia had significantly higher serum thrombopoietin levels (mean 309.63 pg/ml) compared to women with normal pregnancies (mean 215.69 pg/ml, p<0.001).
Why the study?
Preeclampsia is a major cause of maternal and fetal morbidity and mortality, prompting investigation into maternal serum levels of thrombopoietin in this population.
Case-Control (n=88)
No
Absolute Event Rate: 309.63% vs 215.69%
p-value: p=<0.001
Serum thrombopoietin levels are significantly elevated in pregnant women with preeclampsia, suggesting a potential role as a biomarker for the condition.
Thrombopoietin elevation was associated with preeclampsia; leaves open its biomarker utility pending prospective validation.
Background: Preeclampsia is a syndrome and considered one of the most significant causes that can lead to maternal and fetal morbidity and mortality. It is characterized by new onset of hypertension and proteinuria after 20 weeks of gestation. Thrombopoietin is a major regulator of megakaryocyte maturation and platelet production. Thrombopoietin initiates its biologic effects by binding to the myeloproliferative leukemia protein receptor, which is a member of the hematopoietin receptor family. Aims of the study: The present study is intended to compare the maternal serum levels of thrombopoietin between preeclamptic pregnant women and pregnant women without preeclampsia (normal pregnancy).
No takes yet. Share an insight, caveat, or question.
Tauma et al. (2020) conducted a case-control in Preeclampsia (n=88). Preeclampsia vs. Normal pregnancy was evaluated on Serum thrombopoietin level (pg/ml) (p=<0.001). Pregnant women with preeclampsia had significantly higher serum thrombopoietin levels (mean 309.63 pg/ml) compared to women with normal pregnancies (mean 215.69 pg/ml, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: